Afficher la notice abrégée

Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/ French-Language Oncology Group (GOLF)

dc.rights.licenseopenen_US
dc.contributor.authorGREILLIER, Laurent
dc.contributor.authorGAUVRIT, Manon
dc.contributor.authorPAILLAUD, Elena
dc.contributor.authorGIRARD, Nicolas
dc.contributor.authorMONTEGUT, Coline
dc.contributor.authorBOULAHSSASS, Rabia
dc.contributor.authorWISLEZ, Marie
dc.contributor.authorPAMOUKDJIAN, Frederic
dc.contributor.authorCORRE, Romain
dc.contributor.authorCABART, Mathilde
dc.contributor.authorCAILLET, Philippe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELAROUSSI, Yaniss
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFRASCA, Matthieu
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
dc.contributor.authorWANG, Pascal
dc.contributor.authorMEBARKI, Soraya
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
dc.contributor.authorCOUDERC, Anne-Laure
dc.date.accessioned2022-03-16T07:49:42Z
dc.date.available2022-03-16T07:49:42Z
dc.date.issued2022-02-02
dc.identifier.issn2072-6694en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136470
dc.description.abstractEnSystematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI for older patients. A multidisciplinary task force from the French Society of Geriatric Oncology (SoFOG) and the French Society of Pulmonology/Oncology Group (SPLF/GOLF) conducted a systematic review from May 2010 to May 2021. Protocol registered in Prospero under number CRD42021224103. Three key questions were selected for older patients with NSCLC: (1) to whom TKI can be proposed, (2) for whom monotherapy should be favored, and (3) to whom a combination of TKI can be proposed. Among the 534 references isolated, 52 were included for the guidelines. The expert panel analysis concluded: (1) osimertinib 80 mg/day is recommended as a first-line treatment for older patients with the EGFR mutation; (2) full-dose first generation TKI, such as erlotinib or gefitinib, is feasible; (3) ALK and ROS1 rearrangement studies including older patients were too scarce to conclude on any definitive recommendations; and (4) given the actual data, TKI should be prescribed as monotherapy. Malnutrition, functional decline, and the number of comorbidities should be assessed primarily before TKI initiation. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enLung cancer
dc.subject.enTargeted therapy
dc.subject.enEfficacy
dc.subject.enToxicity
dc.subject.enSafety
dc.subject.enQuality of life
dc.subject.enGeriatric assessment
dc.title.enTargeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/ French-Language Oncology Group (GOLF)
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/cancers14030769en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35159036en_US
bordeaux.journalCancersen_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2022-02-02&rft.volume=14&rft.issue=3&rft.eissn=2072-6694&rft.issn=2072-6694&rft.au=GREILLIER,%20Laurent&GAUVRIT,%20Manon&PAILLAUD,%20Elena&GIRARD,%20Nicolas&MONTEGUT,%20Coline&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_cancers_2022_Greillier.pdf
Taille:
711.8Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée